Biodesix (NASDAQ:BDSX) Posts Earnings Results, Beats Estimates By $0.01 EPS

Biodesix (NASDAQ:BDSX - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.01, Zacks reports. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%.

Biodesix Stock Down 10.1 %

Shares of NASDAQ:BDSX traded down $0.08 during trading hours on Monday, hitting $0.71. The company's stock had a trading volume of 402,962 shares, compared to its average volume of 384,435. The firm's fifty day moving average price is $1.14 and its 200 day moving average price is $1.43. Biodesix has a 52 week low of $0.70 and a 52 week high of $2.04. The company has a market capitalization of $103.72 million, a price-to-earnings ratio of -1.83 and a beta of 1.06. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40.

Insider Activity at Biodesix

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of the company's stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now owns 701,947 shares in the company, valued at $645,791.24. This represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 128,702 shares of company stock valued at $118,406 over the last ninety days. 69.20% of the stock is owned by company insiders.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.